[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:tp53-gene":3},{"name":4,"total":5,"recruiting":6,"trials":7},"TP53 Gene",80,68,[8,16,23,30,36,42,48,54,61,67,73,79,85,91,97,103,109,115,121,127,133,139,145,151,157,163,168,174,180,186,192,197,203,209,215,221,226,232,238,244,250,256,262,268,274,279,285,291,297,302],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT03675893","RESOLVE: Abemaciclib + Letrozole +\u002F- Metformin or Gedatolisib in Endometrial Cancer",[12],"Phase 2","RECRUITING","2026-08-26T02:16:36.513735Z","2026-07-05T05:32:16.773482Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT06492707","DR-18 to Prevent or Treat Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse After Hematopoietic Cell Transplantation, the DR. DREAM Trial",[20],"Phase 1","2026-08-03T00:57:52.718762Z","2026-07-05T05:32:16.757562Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT06386146","JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation",[27],"Phase 1\u002FPhase 2","2026-08-26T02:19:02.550788Z","2026-07-05T05:32:16.751547Z",{"nct_id":31,"title":32,"phases":33,"status":13,"updated_at":34,"content_modified":35},"NCT07222215","PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)",[12],"2026-08-26T02:18:23.582895Z","2026-07-05T05:32:16.667982Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT07200102","Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma",[20],"2026-08-26T02:18:25.327036Z","2026-07-05T05:32:16.663314Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":46,"content_modified":47},"NCT07053436","Horizon Two: HR NDMM (MMRC-100)",[12],"2026-08-26T02:17:59.904383Z","2026-05-29T15:36:40.182475Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":52,"content_modified":53},"NCT07566364","Phase 2 Study Of Mosunetuzumab In Patients With Chronic Lymphocytic Leukemia With Positive MRD",[12],"2026-08-26T02:19:03.581490Z","2026-05-13T02:55:06.731598Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":59,"content_modified":60},"NCT07342478","ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R\u002FR CLL\u002FSLL",[58],"Phase 3","2026-08-26T02:18:31.164304Z","2026-05-13T02:55:06.695894Z",{"nct_id":62,"title":63,"phases":64,"status":13,"updated_at":65,"content_modified":66},"NCT04855695","Avo In R\u002FR And Previously Untreated MCL",[27],"2026-08-26T02:18:46.948970Z","2026-05-05T02:47:14.265444Z",{"nct_id":68,"title":69,"phases":70,"status":13,"updated_at":71,"content_modified":72},"NCT05641831","Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study",[12],"2026-08-26T02:15:45.413021Z","2026-05-05T02:43:29.648361Z",{"nct_id":74,"title":75,"phases":76,"status":13,"updated_at":77,"content_modified":78},"NCT06616636","A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)",[20],"2026-08-26T02:19:10.436356Z","2026-05-05T02:43:29.528676Z",{"nct_id":80,"title":81,"phases":82,"status":13,"updated_at":83,"content_modified":84},"NCT07104799","Momelotinib During and After HCT in Myelofibrosis",[20],"2026-08-26T02:17:45.190188Z","2026-05-05T02:43:29.498826Z",{"nct_id":86,"title":87,"phases":88,"status":13,"updated_at":89,"content_modified":90},"NCT07053059","Phase 2 Study Assessing the Clinical Activity and Safety of Obecabtagene Autoleucel as a Consolidation in Patients With Newly Diagnosed High-risk B-cell Acute Lymphocytic Leukemia (ALL)",[12],"2026-08-26T02:18:19.586423Z","2026-05-05T02:43:29.369796Z",{"nct_id":92,"title":93,"phases":94,"status":13,"updated_at":95,"content_modified":96},"NCT07008638","Phase I\u002FII Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)",[27],"2026-08-26T02:18:51.833592Z","2026-05-05T02:43:29.192717Z",{"nct_id":98,"title":99,"phases":100,"status":13,"updated_at":101,"content_modified":102},"NCT05208307","Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma",[12],"2026-08-26T02:17:40.683658Z","2026-05-05T02:43:29.069274Z",{"nct_id":104,"title":105,"phases":106,"status":13,"updated_at":107,"content_modified":108},"NCT06738303","Cabazitaxel +\u002F- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer",[12],"2026-08-26T02:15:59.318403Z","2026-05-05T02:43:29.025195Z",{"nct_id":110,"title":111,"phases":112,"status":13,"updated_at":113,"content_modified":114},"NCT05861050","Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma",[27],"2026-08-26T02:19:25.538428Z","2026-05-05T02:43:28.958425Z",{"nct_id":116,"title":117,"phases":118,"status":13,"updated_at":119,"content_modified":120},"NCT06623110","Phase II Study of RP2 as Immunoprevention in High-Risk Oral Precancerous Disease",[12],"2026-08-26T02:16:32.589113Z","2026-05-05T02:43:28.883549Z",{"nct_id":122,"title":123,"phases":124,"status":13,"updated_at":125,"content_modified":126},"NCT06313437","Revumenib in Combination With 7+3 + Midostaurin in AML",[20],"2026-08-26T02:16:56.877406Z","2026-05-05T02:43:28.835411Z",{"nct_id":128,"title":129,"phases":130,"status":13,"updated_at":131,"content_modified":132},"NCT06357676","Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial",[27],"2026-08-26T02:15:02.712396Z","2026-05-05T02:43:28.817702Z",{"nct_id":134,"title":135,"phases":136,"status":13,"updated_at":137,"content_modified":138},"NCT04659616","Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia",[20],"2026-08-26T02:15:36.077529Z","2026-05-05T02:43:28.717298Z",{"nct_id":140,"title":141,"phases":142,"status":13,"updated_at":143,"content_modified":144},"NCT03661307","Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome",[27],"2026-08-26T02:18:00.873391Z","2026-05-05T02:43:28.288010Z",{"nct_id":146,"title":147,"phases":148,"status":13,"updated_at":149,"content_modified":150},"NCT04169737","Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",[12],"2026-08-26T02:18:33.598205Z","2026-05-05T02:43:28.287166Z",{"nct_id":152,"title":153,"phases":154,"status":13,"updated_at":155,"content_modified":156},"NCT07198074","Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer",[58],"2026-08-26T02:18:36.226508Z","2026-05-05T02:43:28.219924Z",{"nct_id":158,"title":159,"phases":160,"status":13,"updated_at":161,"content_modified":162},"NCT06285890","Phase I Study of HC-7366 for Acute Myeloid Leukemia",[20],"2026-08-26T02:15:34.659160Z","2026-05-05T02:43:28.182174Z",{"nct_id":164,"title":165,"phases":166,"status":13,"updated_at":46,"content_modified":167},"NCT06207799","Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma",[12],"2026-05-05T02:43:28.173865Z",{"nct_id":169,"title":170,"phases":171,"status":13,"updated_at":172,"content_modified":173},"NCT06152809","CIML NK Cells With Venetoclax for AML",[20],"2026-08-26T02:15:47.754948Z","2026-05-05T02:43:28.162326Z",{"nct_id":175,"title":176,"phases":177,"status":13,"updated_at":178,"content_modified":179},"NCT07372625","A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.",[20],"2026-08-26T02:17:22.153941Z","2026-05-05T02:43:27.994124Z",{"nct_id":181,"title":182,"phases":183,"status":13,"updated_at":184,"content_modified":185},"NCT06085729","Phase I\u002FII Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)",[27],"2026-08-26T02:17:57.997171Z","2026-05-05T02:43:27.927821Z",{"nct_id":187,"title":188,"phases":189,"status":13,"updated_at":190,"content_modified":191},"NCT07257055","Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 Study",[12],"2026-08-26T02:18:12.612955Z","2026-05-05T02:43:27.813302Z",{"nct_id":193,"title":194,"phases":195,"status":13,"updated_at":40,"content_modified":196},"NCT06667141","Phase 1 Study of ACR-2316 in Specific Advanced Solid Tumors",[20],"2026-05-05T02:43:27.606583Z",{"nct_id":198,"title":199,"phases":200,"status":13,"updated_at":201,"content_modified":202},"NCT05469893","Immuno-PRISM (PRecision Intervention Smoldering Myeloma)",[12],"2026-08-26T02:18:55.570428Z","2026-05-05T02:43:27.482255Z",{"nct_id":204,"title":205,"phases":206,"status":13,"updated_at":207,"content_modified":208},"NCT04678401","IS-free Treg HaploHCT",[20],"2026-08-26T02:19:12.219640Z","2026-05-05T02:35:31.698703Z",{"nct_id":210,"title":211,"phases":212,"status":13,"updated_at":213,"content_modified":214},"NCT07060989","A Study of Safety, Tolerability and Preliminary Efficacy of NTS071 in Subjects With Advanced Solid Tumors Harboring a TP53 Y220C Mutation",[27],"2026-08-26T02:16:27.227548Z","2026-05-05T02:35:31.649024Z",{"nct_id":216,"title":217,"phases":218,"status":13,"updated_at":219,"content_modified":220},"NCT03128879","Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL",[12],"2026-08-03T03:15:35.967581Z","2026-04-29T02:57:57.177996Z",{"nct_id":222,"title":223,"phases":224,"status":13,"updated_at":59,"content_modified":225},"NCT06434064","Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer",[12],"2026-04-29T02:57:57.103162Z",{"nct_id":227,"title":228,"phases":229,"status":13,"updated_at":230,"content_modified":231},"NCT06138587","Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation",[20],"2026-08-26T02:15:58.452248Z","2026-06-17T19:21:16.690731Z",{"nct_id":233,"title":234,"phases":235,"status":13,"updated_at":236,"content_modified":237},"NCT05691465","Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells",[12],"2026-08-26T02:15:21.365312Z","2026-05-05T02:43:28.481085Z",{"nct_id":239,"title":240,"phases":241,"status":13,"updated_at":242,"content_modified":243},"NCT06834282","CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)",[20],"2026-08-26T02:18:21.216897Z","2026-05-05T02:43:27.841989Z",{"nct_id":245,"title":246,"phases":247,"status":13,"updated_at":248,"content_modified":249},"NCT04187105","BMT-06: Study of Intensity Modulated Total Marrow Irradiation (IM-TMI)",[12],"2026-08-26T02:17:44.240289Z","2026-05-05T02:43:27.748653Z",{"nct_id":251,"title":252,"phases":253,"status":13,"updated_at":254,"content_modified":255},"NCT03824483","Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)",[12],"2026-08-26T02:15:09.079045Z","2026-05-05T02:43:27.422581Z",{"nct_id":257,"title":258,"phases":259,"status":13,"updated_at":260,"content_modified":261},"NCT05098613","Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R\u002FR B-NHL Patients",[20],"2026-08-26T02:16:59.895916Z","2026-07-19T19:36:05.125264Z",{"nct_id":263,"title":264,"phases":265,"status":13,"updated_at":266,"content_modified":267},"NCT05877599","A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation",[20],"2026-08-26T02:15:10.362237Z","2026-07-19T19:36:05.120541Z",{"nct_id":269,"title":270,"phases":271,"status":13,"updated_at":272,"content_modified":273},"NCT05548296","A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma",[12],"2026-08-26T02:17:49.709549Z","2026-07-05T05:32:16.808746Z",{"nct_id":275,"title":276,"phases":277,"status":13,"updated_at":254,"content_modified":278},"NCT07566377","Cord Blood Transplantation in Children and Young Adults With Blood Cancer",[12],"2026-05-13T02:55:06.730274Z",{"nct_id":280,"title":281,"phases":282,"status":13,"updated_at":283,"content_modified":284},"NCT04329728","The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies",[27],"2026-08-26T02:15:48.613507Z","2026-05-05T02:43:28.628795Z",{"nct_id":286,"title":287,"phases":288,"status":13,"updated_at":289,"content_modified":290},"NCT06904066","Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies",[20],"2026-08-26T02:18:59.761994Z","2026-05-05T02:43:27.428326Z",{"nct_id":292,"title":293,"phases":294,"status":13,"updated_at":295,"content_modified":296},"NCT04585750","The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)",[27],"2026-08-26T02:17:46.653867Z","2026-05-05T02:43:27.334679Z",{"nct_id":298,"title":299,"phases":300,"status":13,"updated_at":172,"content_modified":301},"NCT06778863","A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation",[20],"2026-05-05T02:43:26.672516Z",{"nct_id":303,"title":304,"phases":305,"status":13,"updated_at":306,"content_modified":307},"NCT04913064","Effects of White Button Mushroom on Inflammation in Obese Postmenopausal Women at High Risk of Breast Cancer",[],"2026-08-26T02:17:58.890423Z","2026-05-05T02:43:27.487085Z"]